The present disclosure provides a hairball remedy paste for cats, including collagen, sodium carboxymethylcellulose, bone glue, chicken liver powder, chicken meal, edible oil, fructooligosaccharide, hydrolyzed fish protein powder, maltitol, Saccharomyces cerevisiae extract, glycerol, barley seedling powder, vitamin nano-liposomes, protein chelated mineral, potassium iodide, taurine, and water. The hairball remedy paste for cats does not contain mineral oil, and does not affect the absorption of nutrient substances by intestines and stomach after long-term use. Through the synergistic effect of edible oil, fructooligosaccharide, and barley seedling powder, it is conducive to help cats to discharge hairs in intestines and stomach through feces, which can effectively prevent the occurrence of the trichobezoar and improve the constipation of cats.

The present invention relates to a Lactobacillus acidophilus KBL409 strain and uses thereof, wherein the Lactobacillus acidophilus KBL409 (deposit number KCTC 13518BP) strain according to the present invention reduces inflammation of the kidney, reduce the concentration of uremic toxins such as blood urea nitrogen, creatinine and p-cresol to protect the kidney, and thus may be usefully utilized for prophylactic and therapeutic applications of renal diseases including improving renal function and chronic renal failure.

The present invention relates to a Lactobacillus acidophilus KBL409 strain and uses thereof, wherein the Lactobacillus acidophilus KBL409 (deposit number KCTC 13518BP) strain according to the present invention reduces inflammation of the kidney, reduce the concentration of uremic toxins such as blood urea nitrogen, creatinine and p-cresol to protect the kidney, and thus may be usefully utilized for prophylactic and therapeutic applications of renal diseases including improving renal function and chronic renal failure.

The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioactive agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.

The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioactive agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.

The present invention relates to a lipoteichoic acid isolated from Bifidobacteria cultured in excess of glucose which has fat reduction activity, thus being useful for exploitation in the following application areas: food and beverages, animal feed, including pet food, nutritional supplements, infant nutrition, cosmetics (including nutricosmetics), medical foods and pharmaceutical and veterinary applications, among others.

The present invention relates to a lipoteichoic acid isolated from Bifidobacteria cultured in excess of glucose which has fat reduction activity, thus being useful for exploitation in the following application areas: food and beverages, animal feed, including pet food, nutritional supplements, infant nutrition, cosmetics (including nutricosmetics), medical foods and pharmaceutical and veterinary applications, among others.

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

A pet kibble containing from about 20 to 35 wt. % total protein, from about 10 to 15 wt. % edible fat, and from about 10 to 15 wt. % edible fiber. About 70 to 100 wt. % of the protein is plant-sourced. About 3 to 10 wt. % of edible fat is a combination of omega-6 and omega-3 oils. The pet kibble is essentially free of gluten, milk products, peanuts, tree nuts and wheat. The pet kibble is made by an extrusion process that includes flash baking the extrudate, wherein the flash baking is done at from about 450 to 525° F. for from about 30 to 50 seconds.

The present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill specifically Lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12686BP), and a method for preventing and treating the infections of Lactococcus garvieae using the composition comprising said bacteriophage as an active ingredient.